Janssen hands back rights to imetelstat
Janssen Biotech has decided to terminate a collaboration and license agreement with Geron Corp for experimental cancer drug imetelstat.
Read More
Tag: blood cancers
- Nuclera extends Series C funding to advance antibody engineering
- Cellistic launches new iPSC-based platforms to expand immuno-oncology therapies
- Fabentech secures French approval for Ricimed antidote
- Oxford Drug Design reports major in vivo milestone for novel cancer therapy
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
